Biogen boosts investment in neurology with $1 billion Ionis deal

(Reuters) – Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company’s potential blockbuster drug for spinal muscular atrophy. A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder Biogen’s shares, however, fell …

Read More »